NEW YORK – Biosplice Therapeutics is partnering with Epic Sciences to incorporate multiomic profiling into Biosplice's clinical oncology programs, the companies said on Thursday.
As part of the collaboration, Biosplice plans to use Epic's liquid biopsy platform to characterize drug activity and patient response for its Cirtuvivint (SM08502) investigative drug in two clinical trials.
Cirtuvivint, one of Biosplice's lead therapeutic candidates, is a small molecule oral inhibitor of the CDC-like kinase and dual-specificity tyrosine regulated kinase family. The two ongoing trials explore its safety, tolerability, and primary efficacy in several solid tumor indications.
Financial details of the collaboration were not disclosed.
Epic's liquid biopsy platform "provides the opportunity to characterize late-stage cancer patients both phenotypically and genotypically," Darrin Beaupre, chief medical officer at Biosplice Therapeutics, said in a statement. "This is a critical part of our clinical trial as it allows us to better understand both the underlying biology and therapeutic response of the patient."
Epic has ample experience characterizing cancers. Earlier this month, the company said it is preparing to launch its DefineMBC lab-developed test, aimed at comprehensively profiling metastatic breast cancers when a tissue biopsy is unavailable.